Alzheimer's: Simple Drug Change Could Save Medicare Hundreds of Millions
Medicare could save millions of dollars every year by changing the way they package Alzheimer's medication.
Pioneering Alzheimer's drug rejected for widespread use in NHS in England
This is the second time a new Alzheimer's treatment has been rejected by the health spending watchdog in a matter of months.
Daily Express1d
Alzheimer’s £60k wonderdrug blocked on NHS over cost despite major breakthrough
The drug, and another new drug for Alzheimer's called lecanemab, have been billed as a huge step forward in research because ...
i1d
Second Alzheimer’s ‘wonder drug’ blocked for use on NHS due to high costs
NHS spending watchdog says donanemab - available to 70,000 people in England and Wales - 'does not currently demonstrate ...
Donanemab – what we know about the latest Alzheimer’s drug
Donanemab is a targeted antibody drug which slows down the early stages of Alzheimer’s. The drug, and another new drug for Alzheimer’s called lecanemab, have been billed as a huge step forward in ...
NHS will not fund new drug to slow Alzheimer’s
A new drug that slows the pace of Alzheimer's disease is too expensive for too little benefit to be used on the NHS, the ...
The American Journal of Managed Care10d
Discarded Lecanemab Leads to Medicare Drug Waste of Up to $336 Million
Lecanemab (Leqembi; Eisai/Biogen) received traditional approval from the FDA in July 2023, following an accelerated approval ...
Surrey Alzheimer's drug trial patient shares his experience of donanemab
Diagnosed with mild cognitive impairment (MCI) in 2018, Mr Almond, from Esher, took part in two 18-month trials for donanemab ...
startsat60.com1d
Dementia Australia ‘disappointed’ after medical watchdog rejects new Alzheimer’s drug
Dementia Australia, the national peak body that supports people living with dementia, said it is "disappointed" after the ...
Alzheimer's drug that slows down disease rejected for widespread use on the NHS
People will not be able to access the drug, which slows progression of the disease by four to seven months, on the NHS ...
Alzheimer’s drug rejected for widespread use by NHS spending watchdog
A new Alzheimer’s drug has been rejected for widespread use in the health service in England after the health spending watchdog said it “does not currently demonstrate value for the NHS”. The news ...
New Alzheimer’s drug donanemab rejected for widespread use in NHS
A new Alzheimer’s drug has been rejected by the health spending watchdog for general use within NHS England, with the ...